GO
Loading...

Pharmaceuticals

More

  • UPDATE 1-Gilead's experimental drug fails mid-stage study Wednesday, 17 Sep 2014 | 6:47 AM ET

    Sept 17- Gilead Sciences Inc said its experimental drug did not significantly improve how long patients with a type of pancreatic cancer lived without the disease worsening. Separately, the biotechnology company also licensed Sovaldi to seven India- based drugmakers that will sell far cheaper versions of the drug in 91 developing nations.

  • NEW YORK, Sept 16- Some of the top 20 investors at Salix Pharmaceuticals Ltd are threatening to vote down a proposed deal to buy a unit of Cosmo Pharmaceuticals SpA, and are pressing Salix to consider selling itself instead, people familiar with the matter said on Tuesday.

  • Nektar says FDA clears constipation drug Movantik Tuesday, 16 Sep 2014 | 2:01 PM ET

    British drugmaker AstraZeneca PLC will market the drug, and it has also filed for regulatory approval in the European Union and Canada. The San Francisco company said Movantik will be available to patients in the first half of 2015. AstraZeneca will conduct a study to evaluate the drug's cardiovascular side effects. AstraZeneca stock fell 9 cents to $73.69.

  • Lilly, AstraZeneca team up on Alzheimer's drug Tuesday, 16 Sep 2014 | 10:36 AM ET

    INDIANAPOLIS— Eli Lilly and Co. plans to pay up to $500 million to fellow drugmaker AstraZeneca as part of a collaboration to develop and sell a potential Alzheimer's disease treatment that is in the early stages of clinical testing.

  • Sept 16- Siga Technologies Inc, a supplier of antiviral smallpox drug to the U.S. strategic stockpile, filed for voluntary bankruptcy protection as it seeks time to appeal a court order favoring PharmAthene Inc in a licensing dispute.

  • Drugmaker Siga Technologies files for bankruptcy Tuesday, 16 Sep 2014 | 7:10 AM ET

    Sept 16- Siga Technologies Inc filed for voluntary bankruptcy protection on Tuesday and said the filing was to preserve its ability to supply its antiviral smallpox drug to the U.S. Siga listed total assets of $209.5 million and liabilities of $197.9 million in its Chapter 11 petition with the Southern District of New York.

  • Ebola under the microscope     Tuesday, 16 Sep 2014 | 6:35 AM ET

    CNBC's Meg Tirrell, and Scott Gottlieb, American Enterprise Institute, discuss the latest developments in controlling the Ebola epidemic.

  • Allergan agrees to move forward with meeting Tuesday, 16 Sep 2014 | 6:35 AM ET

    NEW YORK— Allergan and Pershing Square have agreed on at least one step toward settling a fight over the makeup of the Botox-maker's board. Allergan will hold its special shareholders meeting as planned on Dec. 18, while Pershing Square and its partner, Valeant Pharmaceuticals, continue their push for control of the drugmaker.

  • Switzerland takes on its top drugmakers in price row Tuesday, 16 Sep 2014 | 5:46 AM ET

    *Roche, Novartis say low prices hurt R&D. ZURICH, Sept 16- Switzerland, home to the world's two biggest drugmakers, might be expected to give them an easy ride. But Roche and Novartis are finding no immunity in their home market from a European-wide price squeeze.

  • APNewsBreak: NY bid to halt Alzheimer's drug swap Monday, 15 Sep 2014 | 7:02 PM ET

    ALBANY, N.Y.— New York's attorney general filed a federal lawsuit Monday seeking to stop a manufacturer from discontinuing its drug widely used to treat Alzheimer's patients, arguing the company is illegally driving patients to its newer patented drug to avoid losses from cheaper generic alternatives coming out next year.

  • Sept 15- Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.

  • NEW YORK, Sept 15- Biotech stocks were tracking for their third straight decline on Monday, weighed down by a drop in Gilead Sciences after the latest developments regarding its hepatitis C drug.

  • *Gilead plans to sell Sovaldi in India for $300 a month. NEW DELHI/ MUMBAI, Sept 15- U.S. drugmaker Gilead Sciences Inc has licensed its hepatitis C drug Sovaldi to seven India- based drugmakers that will sell far cheaper versions of the $1,000- a-pill medicine in 91 developing nations.

  • *Gilead plans to sell Sovaldi in India for $300 per month. NEW DELHI/ MUMBAI, Sept 15- U.S. drugmaker Gilead Sciences Inc has agreed to license its hepatitis C drug Sovaldi to seven India- based drugmakers to sell cheaper versions of the $1,000- a-pill medicine in 91 developing nations including India.

  • Gilead to license generic version of Sovaldi Monday, 15 Sep 2014 | 7:40 AM ET

    Gilead Sciences has reached a deal with several generic drugmakers to produce a cheaper version of its popular, $1,000- per-pill hepatitis C drug Sovaldi for use in developing countries.

  • Kids' poisonings linked to anti-addiction medicine Monday, 15 Sep 2014 | 12:01 AM ET

    CHICAGO— An anti-addiction drug used to fight the nation's heroin and painkiller abuse epidemics poses a threat to young children who accidentally swallow relatives' prescriptions, a federal study says.

  • Sept 12- Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of an antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the cholesterol drug Lipitor, the best-selling drug in history.

  • LONDON, Sept 12- New European Commission President Jean-Claude Juncker came under fire from health campaigners on Friday for his plan to shift responsibility for medicines to the Commission's industrial division from health.

  • Feds say Bayer colon supplement makes bogus claims Friday, 12 Sep 2014 | 1:29 PM ET

    WASHINGTON— The federal government says Bayer is making unsupported claims in advertisements for its dietary supplement designed to help with digestion, in violation of a federal court order.

  • The candidate Ebola vaccine is being co-developed by the United States National Institutes of Health and the British drugmaker GlaxoSmithKline. The trial will be led by Professor Adrian Hill of the Jenner Institute at Oxford University, which said on Friday the first shot is scheduled to be given to a human volunteer next week.